Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2026)

Evommune (EVMN) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $322.5 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $322.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $631.9 million (changed N/A YoY), and the FY2025 annual result was $224.9 million, up 195.77% from the prior year.
• Liabilities and Shareholders Equity climbed to $322.5 million in Q1 2026 per EVMN's latest filing, from $224.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $322.5 million in Q1 2026 and troughed at $76.1 million in Q4 2024.
• A 3-year average of $177.0 million and a median of $154.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $76.1 million in 2024, then soared by 195.77% to $224.9 million in 2025, then surged by 43.35% to $322.5 million in 2026.
• Business Quant data shows EVMN's Liabilities and Shareholders Equity at $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.